Skip to main content
. 2017 May 26;264(6):1254–1263. doi: 10.1007/s00415-017-8523-y

Fig. 2.

Fig. 2

Prevalence of dyskinesias [a disabling dyskinesias (UPDRS Part IV-items 33 score ≥2) are highlighted in black color] and motor fluctuations (b) in the study population. Controls (Co.) indicate patients who did not receive any monoamine oxidase type B (MAO-B) inhibitor (Ras rasagiline, Sel selegiline)